Belgravia Capital International announces LOI with R&D Pharma Corp.

TORONTO, 2018-01-04 13:00 CET (GLOBE NEWSWIRE) --
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) ("Belgravia
Capital", "Belgravia", or the "Company") is pleased to announce the execution
of a letter of intent with R&D Pharma (the "Letter of Intent"), to collaborate
in the development of Belgravia's distributed and decentralized blockchain
medical cannabis provenance and quality attestation database. 

R&D Pharma Corp., a Canadian private company, is building a vertically
integrated medical cannabis business in the Country of Jamaica. Jamaica has
sophisticated medical cannabis laws in place consistent with the best in class
laws of Canada and Israel.  Further, well recognized international regulated
cannabis production and distribution companies are establishing footholds in
Jamaica due to the recognized quality of the strains and, also Jamaica's
history of medical research in this space.  For example, Dr. Henry Lowe of
Kingston, Jamaica, a specialist in medicinal chemistry, a chemistry-based
discipline involving biological, medical and pharmaceutical sciences, has
contributed 50 years to the fields of biotechnology ethical drug development,
including drug regulatory validated cannabis sativa products, for conditions
such as nausea, pain, appetite stimulation, motion sickness, inflammation, and
high ocular pressure which can lead to glaucoma. 

The provisions of the Letter of Intent with R&D Pharma include:

  -- R&D will provide validated input data regarding concentration of
     Cannabinoids in products, and other active ingredients, and levels of any
     impurities which will be required to be consistent with established
     standards;
  -- R&D will provide references on the blockchain will be provided to
     off-chain documents including hash indexes to reports of independent
     analytical labs for microbiology, heavy metals, pesticides, and
     metabolites;
  -- Belgravia will invite R&D to be a permissioned node on the distributed
     blockchain; and
  -- Revenue sharing models will be negotiated in due course, and as business
     cases are further evaluated, and a significant number of additional
     industry players, regulators, and consumer conduits are established through
     social media marketing and other consumer outreach forums.

It is anticipated that medical cannabis provenance and attestation data will be
encapsulated on the blockchain in both native and encrypted format, and that
detailed supporting hash-proven documents will be searchable through hash
indexes on the blockchain-validated blocks associated with unencrypted
identifiers of products, strains, and other relevant parts of the seed to sale
production blockchain. The blocks will by searchable by domestic and
international consumers, governments, and industry players and other interested
stakeholders or parties. 

Mr. Mehdi Azodi, the President and Chief Executive Officer of Belgravia stated:
"As we have previously communicated we are advancing carefully thought out
plans for the development of Blockchain distributed databases as a service to
retail consumers, and as a value-added technology for the medical cannabis
industry. This work will require the building out of a team of conceptual
thinkers in blockchain business applications, programmers, and marketers to
both industry players and consumers.  Well thought out user interfaces will
need to be developed to support easily accessible consumer searches from smart
phones and point of sales terminals, as well as personal computers, where
software can be downloaded to nodes.  Although some degree of decentralisation
will be maintained in the structure of the medical cannabis attestation
blockchain, a trusted and fully disclosed consortium will grant read write
permissions to other participants. The consortium will be subject to thorough
governance and audit.  Consortium blockchains will be standard for blockchains
being developed in various industries where the intention is to provide
consumer-friendly transparency and social responsibility to consumers,
regulators, governments, and all other stakeholders. Customers and the public
will be able to validate inputs by accessing off-chain database documents,
likely for a reasonable fee.  Belgravia is proud to be part of this industry
and these developments." 

Mr. Azodi continued: "In addition to these developments, the company has
invested approximately $675,000 as it commences to build a portfolio of
strategic research and development investments in companies which will provide
value-added services to Belgravia in terms of profitable ideas and
relationships.  The Company plans to establish a royalty division." 

About Belgravia Capital
Belgravia Capital International is focused on the provision of clearly
value-added services to the international legal Cannabis industry.  This
includes the production of specialized organic fertilizers for Cannabis Sativa
plants, and the organization and development of blockchain technology software
for seed-to-sale tracking and quality attestation of intermediate and consumer
products. The wholly-owned subsidiary of Belgravia, ICP Organics, is a research
and development company incorporating agronomic and health perspectives in the
Cannabis space. Belgravia is also developing a royalty-streaming subsidiary. 

Belgravia Capital intends to establish joint research and development
partnerships with Licensed Producers operating under ACMPR regulations in
Canada and in other jurisdictions where medicinal cannabis is fully legal.
Belgravia Capital may invest in various private and public companies in
diversified sectors on an opportunistic basis. For more information, please
visit www.belgraviacapital.ca. 

Forward-Looking Statements
Certain information set forth in this news release may contain forward-looking
statements that involve substantial known and unknown risks and uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. Forward-looking statements include statements that use
forward-looking terminology such as "may", "will", "expect", "anticipate",
"believe", "continue", "potential" or the negative thereof or other variations
thereof or comparable terminology. Such forward-looking statements include,
without limitation, statements regarding planned investment activities &
related returns, trends in the markets for fertilizers and medicinal or
recreational use of cannabis, the timing or assurance of the legalization of
recreational cannabis, the timing for completion of research and development
activities, the potential value of royalties from water and other resources,
and other statements that are not historical facts. These forward-looking
statements are subject to numerous risks and uncertainties, certain of which
are beyond the control of the Company, including, but not limited to, changes
in market trends, the completion, results and timing of research undertaken by
the Company, risks associated with resource assets, the impact of general
economic conditions, commodity prices, industry conditions, dependence upon
regulatory, environmental, and governmental approvals, the uncertainty of
obtaining additional financing, and risks associated with cannabis use for
medicinal or recreational purposes. Readers are cautioned that the assumptions
used in the preparation of such information, although considered reasonable at
the time of preparation, may prove to be imprecise and, as such, undue reliance
should not be placed on forward-looking statements. 

For More Information, Please Contact:
Mehdi Azodi, President & CEO
Belgravia Capital
[phone]
[e-mail]